España
India
Italia
대한민êµ
日本
My Account
My Account
Notifications
Overview
+ New Watchlist
Benzinga Edge
Benzinga Research
Benzinga Pro
Log In
Get Benzinga Pro
Data & APIs
Events
Premarket
Boost
Advertise
Contribute
España
India
Italia
대한민êµ
日本
Login
Register
Our Services
News
Earnings
Guidance
Dividends
M&A
Buybacks
Legal
Interviews
Management
Offerings
IPOs
Insider Trades
Biotech/FDA
Politics
Healthcare
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Markets
Pre-Market
After Hours
Movers
ETFs
Forex
Cannabis
Commodities
Binary Options
Bonds
Futures
CME Group
Global Economics
Mining
Previews
Small-Cap
Real Estate
Penny Stocks
Digital Securities
Volatility
Options
Ratings
Analyst Color
Downgrades
Upgrades
Initiations
Price Target
Ideas
Trade Ideas
Long Ideas
Short Ideas
Technicals
From The Press
Jim Cramer
Rumors
Whisper Index
Stock of the Day
Best Stocks & ETFs
Best Penny Stocks
Best S&P 500 ETFs
Best Swing Trade Stocks
Best Blue Chip Stocks
Best High-Volume Penny Stocks
Best Small Cap ETFs
Best Stocks to Day Trade
Best REITs
Money
Investing
Cryptocurrency
Mortgage
Insurance
Yield
Personal Finance
Forex
Startup Investing
Real Estate Investing
Prop Trading
Credit Cards
Stock Brokers
Crypto
Cannabis
Cannabis Conference
Earnings
Interviews
Deals
Regulations
Psychedelics
Research
My Stocks
Tools
Free Benzinga Pro Trial
Calendars
Analyst Ratings Calendar
Conference Call Calendar
Dividend Calendar
Earnings Calendar
Economic Calendar
FDA Calendar
Guidance Calendar
IPO Calendar
M&A Calendar
SPAC Calendar
Stock Split Calendar
Trade Ideas
Free Stock Reports
Insider Trades
Trade Idea Feed
Analyst Ratings
Unusual Options Activity
Heatmaps
Free Newsletter
Government Trades
Perfect Stock Portfolio
Easy Income Portfolio
Short Interest
Most Shorted
Largest Increase
Largest Decrease
Calculators
Margin Calculator
Forex Profit Calculator
100x Options Profit Calculator
Recent
Markets
Comments
Close menu
Loading...
Travere Therapeutics
TVTX
NASDAQ
Watchlist
Leave a Comment
Logo brought to you by Benzinga Data
Get Report
Perks
Buy
Compare Brokers
Get Report
Perks
Buy
Compare Brokers
$17.78
0.65
3.79%
At close: -
$17.74
-0.04
-0.22%
After Hours: 4:00 PM EDT
Get Report
Comment
Travere Therapeutics (TVTX) Forecast
News
Earnings
Travere Therapeutics (TVTX) Options
Guidance
Dividends
Analyst Ratings
Insider Trades
Short Interest
Latest news for Travere Therapeutics (NASDAQ:TVTX) Stock
Travere Therapeutics Stock (NASDAQ: TVTX)
Categories: All
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
All News
General
Contracts
Dividends
Events
FDA
M&A
Offerings
Stock Split
Media
Buybacks
Insider Trades
Earnings
Guidance
Analyst Ratings
Trading Ideas
Thursday, November 14, 2024
Piper Sandler Maintains Neutral on Travere Th...
Benzinga Newsdesk
Friday, November 08, 2024
Reported Earlier, Travere Therapeutics Prices...
Benzinga Newsdesk
Thursday, November 07, 2024
Travere Therapeutics Announced A Proposed Pub...
Benzinga Newsdesk
Friday, November 01, 2024
Scotiabank Maintains Sector Outperform on Tra...
Benzinga Newsdesk
Barclays Maintains Overweight on Travere Ther...
Benzinga Newsdesk
Thursday, October 31, 2024
Travere Therapeutics Q3 2024 GAAP EPS $(0.70)...
Benzinga Newsdesk
Wednesday, October 30, 2024
A Preview Of Travere Therapeutics's Earnings
Benzinga Insights
Monday, October 28, 2024
Reported Saturday, Travere Therapeutics Revea...
Benzinga Newsdesk
Wednesday, October 23, 2024
Jim Cramer Says 'Hold On' To Palantir, 'Let Them Walk It Up'; Warns That Travere Therapeutics Is Losing A 'Ton Of Money'
Avi Kapoor
Monday, October 21, 2024
Travere Therapeutics Stock: A Deep Dive Into Analyst Perspectives (24 Ratings)
Benzinga Insights
Wells Fargo Upgrades Travere Therapeutics to ...
Benzinga Newsdesk
Thursday, October 17, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
CSL Vifor And Travere's FILSPARI Receives Tem...
Benzinga Newsdesk
Wednesday, October 16, 2024
Breaking Down Travere Therapeutics: 23 Analysts Share Their Views
Benzinga Insights
Scotiabank Initiates Coverage On Travere Ther...
Benzinga Newsdesk
Monday, October 14, 2024
Travere Therapeutics To Present 11 Abstracts,...
Benzinga Newsdesk
Friday, October 11, 2024
Leerink Partners Maintains Outperform on Trav...
Benzinga Newsdesk
Thursday, October 10, 2024
Top 2 Health Care Stocks That Are Ticking Portfolio Bombs
Avi Kapoor
Wednesday, October 09, 2024
B of A Securities Maintains Buy on Travere Th...
Benzinga Newsdesk
Guggenheim Maintains Buy on Travere Therapeut...
Benzinga Newsdesk
Travere Therapeutics shares are trading highe...
Benzinga Newsdesk
Wedbush Maintains Outperform on Travere Thera...
Benzinga Newsdesk
Tuesday, October 08, 2024
Leerink Partners Reiterates Outperform on Tra...
Benzinga Newsdesk
Tuesday, October 01, 2024
Barclays Maintains Overweight on Travere Ther...
Benzinga Newsdesk
Monday, September 30, 2024
Canaccord Genuity Maintains Buy on Travere Th...
Benzinga Newsdesk
Friday, September 27, 2024
Citigroup Maintains Buy on Travere Therapeuti...
Benzinga Newsdesk
Where Travere Therapeutics Stands With Analysts
Benzinga Insights
Guggenheim Maintains Buy on Travere Therapeut...
Benzinga Newsdesk
Micron To $150? Here Are 10 Top Analyst Forecasts For Friday
Avi Kapoor
B of A Securities Maintains Buy on Travere Th...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Travere ...
Benzinga Newsdesk
Costco, Scholastic And 3 Stocks To Watch Heading Into Friday
Avi Kapoor
Thursday, September 26, 2024
12 Health Care Stocks Moving In Thursday's After-Market Session
Benzinga Insights
Travere Therapeutics shares are trading lower...
Benzinga Newsdesk
Travere Therapeutics Announces Voluntary Paus...
Benzinga Newsdesk
Friday, September 13, 2024
JP Morgan Maintains Overweight on Travere The...
Benzinga Newsdesk
Tuesday, September 10, 2024
Canaccord Genuity Maintains Buy on Travere Th...
Benzinga Newsdesk
Monday, September 09, 2024
Travere Therapeutics shares are trading highe...
Benzinga Newsdesk
This United States Steel Analyst Turns Bullish; Here Are Top 5 Upgrades For Monday
Avi Kapoor
Guggenheim Upgrades Travere Therapeutics to B...
Benzinga Newsdesk
Friday, September 06, 2024
Analyst Ratings For Travere Therapeutics
Benzinga Insights
Citigroup Maintains Buy on Travere Therapeuti...
Benzinga Newsdesk
Quanex Building Products Posts Better-Than-Expected Results, Joins Zumiez, Guidewire Software, Smartsheet And Other Big Stocks Moving Higher On Friday
Avi Kapoor
B of A Securities Maintains Buy on Travere Th...
Benzinga Newsdesk
NIO To Rally Around 65%? Here Are 10 Top Analyst Forecasts For Friday
Avi Kapoor
Travere Therapeutics shares are trading highe...
Benzinga Newsdesk
HC Wainwright & Co. Maintains Buy on Travere ...
Benzinga Newsdesk
Thursday, September 05, 2024
Trading Halt: Halt status updated at 7:05:00 ...
Benzinga Newsdesk
Travere Says FDA Has Granted Full Approval To...
Benzinga Newsdesk
Trading Halt: Halted at 4:34:47 p.m. ET - Tra...
Benzinga Newsdesk
Show More
Create a Watchlist
FREE: Follow your stocks and cryptocurrencies with the most actionable alerts on the internet.
Click to Get Started
People Also Watch